SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FibroGen, Inc. today announced that pharmacologic stabilization of hypoxia-inducible factor (HIF) using the company’s proprietary small molecule inhibitors of HIF-prolyl hydroxylase (HIF-PH) prevented brain tissue damage and preserved motor function in a preclinical model of transient ischemic stroke. The data were presented in the late-breaking abstract session held yesterday evening at the International Stroke Conference (ISC) 2007 (Poster # LB P15).
